Zobrazeno 1 - 10
of 269
pro vyhledávání: '"Muhit, Ozcan"'
Autor:
Guldane Cengiz Seval, Sinem Civriz Bozdag, Selami Kocak Toprak, Meltem Kurt Yuksel, Pervin Topcuoglu, Onder Arslan, Taner Demirer, Gunhan Gurman, Meral Beksac, Osman Ilhan, Muhit Ozcan
Publikováno v:
Balkan Medical Journal, Vol 40, Iss 3, Pp 197-204 (2023)
Background: Allogeneic hematopoietic stem cell transplantation is a well-established approach for patients diagnosed with primary myelofibrosis and remains the only potentially curative treatment. Aims: To present the overall outcome of patients wit
Externí odkaz:
https://doaj.org/article/31bb8173591949c6905e9d512718c6ce
Autor:
Muhit Ozcan, Yuqin Song, Seung Tae Lee, Felix Mensah, Dipenkumar Modi, Alexander Fossa, Won Seog Kim, Ewa Paszkiewicz-Kozik, Yazeed Sawalha, Omur Gokmen Sevindik, Lalita Norasetthada, Armando Santoro, Kumudu Pathiraja, Samhita Chakraborty, Patricia Marinello, David Lavie
Publikováno v:
HemaSphere, Vol 7, p e03345ef (2023)
Externí odkaz:
https://doaj.org/article/5aca785fd435480da499be81ff0b9ce3
Autor:
Hulya Yilmaz, Guldane Cengiz Seval, Selami Kocak Toprak, Meltem Kurt Yuksel, Pervin Topcuoglu, Onder Arslan, Taner Demirer, Isinsu Kuzu, Meral Beksac, Muhit Ozcan
Publikováno v:
HemaSphere, Vol 7, p e583935d (2023)
Externí odkaz:
https://doaj.org/article/56fc9e5be4f04be6b2b690ccaf9384bd
Autor:
Guldane Cengiz Seval, Ekin Kircali, Derya Koyun, Bulent Karakaya, Hulya Yilmaz, Gul Yavuz, Hakan Akbulut, Selami Kocak Toprak, Pervin Topcuoglu, Onder Arslan, Muhit Ozcan, Osman Ilhan, Meral Beksac
Publikováno v:
HemaSphere, Vol 6, Pp 26-26 (2022)
Externí odkaz:
https://doaj.org/article/08a62f24c8b744be884a7c2ca65375fc
Autor:
Zehra Narli Ozdemir, Ekin Kircali, Uğur Şahin, Guldane Cengiz Seval, Sinem Civriz Bozdağ, Selami Kocak Toprak, Meltem Kurt Yuksel, Pervin Topcuoglu, Onder Arslan, Taner Demirer, Osman Ilhan, Meral Beksac, Gunhan Gurman, Muhit Ozcan
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:596-600
The benefit of pre-transplant consolidation in patients with acute lymphoblastic leukemia (ALL) who achieved first complete remission (CR1) has not yet been clearly demonstrated. Here, we aimed to investigate the relationship between the treatments r
Autor:
Elif Birtas Atesoglu, Zafer Gulbas, Ant Uzay, Muhit Ozcan, Fahir Ozkalemkas, Mehmet Sinan Dal, Hakan Kalyon, Olga Meltem Akay, Burak Deveci, Huseyin Bekoz, Omur Gokmen Sevindik, Tayfur Toptas, Fergun Yilmaz, Derya Koyun, Nihan Alkis, Inci Alacacioglu, Mehmet Sonmez, Irfan Yavasoglu, Anil Tombak, Ozgur Mehtap, Fatih Kurnaz, Orhan Kemal Yuce, Volkan Karakus, Mehmet Turgut, Derya Deniz Kurekci, Mesut Ayer, Muzaffer Keklik, Deram Buyuktas, Murat Ozbalak, Burhan Ferhanoglu
Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion trial conducted in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2497f4e81be510fd6626ab724fb52159
https://hdl.handle.net/11424/289907
https://hdl.handle.net/11424/289907
Autor:
Keith W. Pratz, Brian A. Jonas, Vinod Pullarkat, Christian Recher, Andre C. Schuh, Michael J. Thirman, Jacqueline S. Garcia, Courtney D. DiNardo, Vladimir Vorobyev, Nicola S. Fracchiolla, Su-Peng Yeh, Jun Ho Jang, Muhit Ozcan, Kazuhito Yamamoto, Arpad Illes, Ying Zhou, Monique Dail, Brenda Chyla, Jalaja Potluri, Hartmut Döhner
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 8
PURPOSE There is limited evidence on the clinical utility of monitoring measurable residual disease (MRD) in patients with acute myeloid leukemia treated with lower-intensity therapy. Herein, we explored the outcomes of patients treated with venetocl
Autor:
José Salvador Rodrigues de Oliveira, Guilherme Fleury Perini, Pier Luigi Zinzani, Valeria Buccheri, John Kuruvilla, Radhakrishnan Ramchandren, Nathalie A. Johnson, Ying Zhu, Todd L. Saretsky, Michael Dickinson, Armando Santoro, Andrew McDonald, Ewa Paszkiewicz-Kozik, Akash Nahar, Muhit Ozcan, Monika Raut, Naohiro Sekiguchi, Robin Gasiorowski
Publikováno v:
Blood Advances
Key Points Pembrolizumab improved health-related quality of life over brentuximab vedotin in patients with relapsed/refractory cHLPembrolizumab should be considered the preferred treatment option for relapsed/refractory cHL post-ASCT or in patients i
Autor:
Mark P. Hertzberg, Jamie Hirata, Gilles Salles, Laurie H. Sehn, Muhit Ozcan, Grace Ku, Christopher R. Flowers, Alex F. Herrera, Andrew McMillan, Tae Min Kim, Stephen Opat, Lisa Musick, Yi Meng Chang, Violaine Safar, Matthew J. Matasar, Sarit Assouline
Publikováno v:
Blood Advances
Key Points Consistent with previous results, pola + BR has a tolerable safety profile.The survival benefit of pola + BR vs BR persists with longer follow-up; efficacy in the pola + BR extension and randomized arms was similar.
Visual Abstract
Visual Abstract
Autor:
A. M. Zergeroglu, Mustafa Merter, Ibrahim Dundar, Ugur Sahin, Muhit Ozcan, Mehmet Mesut Çelebi, Esen Ismet Oktay
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e15-e25
Background and Aim : This study is designed to investigate the physical, psychological and quality of life (QoL) effects of a 16 week supervised and structured intensive aerobic and strength training during the first line chemotherapy of lymphomas. P